Skip to main content
. Author manuscript; available in PMC: 2014 Sep 3.
Published in final edited form as: Cancer Immunol Immunother. 2011 Jul 27;60(12):1789–1800. doi: 10.1007/s00262-011-1072-9

Fig. 3.

Fig. 3

NK cells from the peritoneal fluid of ovarian cancer patients can bind to huKS-IL2 via CD25. Pretreatment with huKS-IL2 decreased the amount of binding of anti-CD25 mAb to the cell surface, indicating that huKS-IL2 was binding to patient peritoneal fluid NK cells via CD25. NK cells were gated using CD16, CD56 and NKp46. Four patient samples in duplicate (total of eight points per treatment group) are shown in this figure. Statistical analysis was conducted using the matched pair t test. *P <0.05